SAN DIEGO, Feb. 20, 2014 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it will
provide a corporate update and report fourth quarter and full year
2013 financial results after the NASDAQ Global Select Market closes
on Thursday, February 27, 2014. That
same day, Arena will host a conference call and webcast at
5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
The conference call may be accessed by dialing 877.643.7155 for
domestic callers and 914.495.8552 for international callers. Please
specify to the operator that you would like to join the "Arena
Pharmaceuticals' Fourth Quarter and Full Year 2013 Financial
Results Call." The conference call will be webcast live under the
investor relations section of Arena's website at
www.arenapharm.com, and will be archived there for 30 days
following the call. Please connect to Arena's website several
minutes prior to the start of the broadcast to ensure adequate time
for any software download that may be necessary.
About Arena Pharmaceuticals
Arena is a biopharmaceutical company focused on discovering,
developing and commercializing novel drugs that target G
protein-coupled receptors, or GPCRs, to address unmet medical
needs. BELVIQ® (lorcaserin HCl), Arena's internally
discovered drug, is approved for marketing in the United States and is under review for
regulatory approval in additional territories. Arena's US
operations are located in San Diego,
California, and its operations outside of the United States, including its commercial
manufacturing facility, are located in Zofingen, Switzerland. For more information, visit
Arena's website at www.arenapharm.com.
Arena Pharmaceuticals® and Arena® are registered service marks
of Arena Pharmaceuticals, Inc. BELVIQ® is a registered
trademark of Arena Pharmaceuticals GmbH.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about the marketing,
regulatory review and approval of BELVIQ; and Arena's focus, plans,
goals, strategy, expectations, research and development programs,
and ability to discover and develop compounds and commercialize
drugs. For such statements, Arena claims the protection of the
Private Securities Litigation Reform Act of 1995. Actual events or
results may differ materially from Arena's expectations. Factors
that could cause actual results to differ materially from the
forward-looking statements include, but are not limited to, the
following: risks related to commercializing drugs, including
regulatory, manufacturing, supply and marketing issues and the
availability and use of BELVIQ; cash and revenues generated from
BELVIQ, including the impact of competition; Arena's revenues will
be based in part on estimates, judgment and accounting policies,
and incorrect estimates or disagreement regarding estimates or
accounting policies may result in changes to Arena's guidance or
previously reported results; the timing and outcome of regulatory
review is uncertain, and BELVIQ may not be approved for marketing
when expected or ever in combination with another drug, for another
indication or using a different formulation or in any other
territory for any indication; regulatory decisions in one territory
may impact other regulatory decisions and Arena's business
prospects; government and commercial reimbursement and pricing
decisions; risks related to relying on collaborative arrangements;
the timing and receipt of payments and fees, if any, from
collaborators; the entry into or modification or termination of
collaborative arrangements; unexpected or unfavorable new data;
nonclinical and clinical data is voluminous and detailed, and
regulatory agencies may interpret or weigh the importance of data
differently and reach different conclusions than Arena or others,
request additional information, have additional recommendations or
change their guidance or requirements before or after approval;
data and other information related to any of Arena's research and
development may not meet regulatory requirements or otherwise be
sufficient for (or Arena or a collaborator may not pursue) further
research and development, regulatory review or approval or
continued marketing; Arena's ability to obtain and defend patents;
the timing, success and cost of Arena's research and development;
results of clinical trials and other studies are subject to
different interpretations and may not be predictive of future
results; clinical trials and other studies may not proceed at the
time or in the manner expected or at all; having adequate funds;
and satisfactory resolution of litigation or other disagreements
with others. Additional factors that could cause actual results to
differ materially from those stated or implied by Arena's
forward-looking statements are disclosed in Arena's filings with
the Securities and Exchange Commission. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Contact: Arena Pharmaceuticals, Inc.
|
Media Contact: Russo
Partners
|
|
|
Cindy McGee, Vice President,
|
David Schull,
President
|
Investor Relations & Alliance Management
|
david.schull@russopartnersllc.com
|
cmcgee@arenapharm.com
858.453.7200, ext. 1479
www.arenapharm.com
|
858.717.2310
|
SOURCE Arena Pharmaceuticals, Inc.